Danaher’s fourth quarter results met Wall Street’s revenue expectations, with management attributing performance to ongoing strength in its bioprocessing segment and steady growth in diagnostics. CEO Rainer Blair noted that bioprocessing consumables demand, especially for monoclonal antibodies, remained robust, while diagnostic platforms benefited from an active respiratory season and expanding test menus. However, management acknowledged ongoing softness in academic and government research funding, with Blair describing these end markets as “muted but stable.” The company also cited the impact of productivity initiatives and continued investment in new product development as central to offsetting cost pressures.
Is now the time to buy DHR? Find out in our full research report (it’s free for active Edge members).
Danaher (DHR) Q4 CY2025 Highlights:
- Revenue: $6.84 billion vs analyst estimates of $6.81 billion (4.6% year-on-year growth, in line)
- Adjusted EPS: $2.23 vs analyst estimates of $2.19 (1.8% beat)
- Adjusted EBITDA: $2.13 billion vs analyst estimates of $2.08 billion (31.1% margin, 2.3% beat)
- Adjusted EPS guidance for the upcoming financial year 2026 is $8.43 at the midpoint, in line with analyst estimates
- Operating Margin: 22%, in line with the same quarter last year
- Organic Revenue rose 2.5% year on year (beat)
- Market Capitalization: $153.1 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Danaher’s Q4 Earnings Call
- Michael Ryskin (Bank of America): Asked about the drivers that could push core revenue growth toward the upper end of guidance. CEO Rainer Blair pointed to further recovery in life sciences and bioprocessing as areas of potential upside.
- Tycho Peterson (Jefferies): Inquired about the strength in SCIEX, questioning how much was from new products versus end market recovery. Blair credited both the Xenotop 8600 launch and a rebound in pharma and clinical markets.
- Scott Davis (Melius Research): Probed for details on restructuring and cost savings. Blair described traditional productivity improvements, including consolidation of facilities and headcount reductions, as the main sources of sustained savings.
- Doug Schenkel (Wolfe Research): Sought clarity on bioprocessing equipment growth guidance and possible demand pull forward. CFO Matt McGrew emphasized caution, noting one quarter’s growth does not establish a trend, so guidance remains conservative.
- Jack Meehan (Nephron Research): Asked about the sustainability of life sciences recovery and the impact of year-end budget flushes. Blair stated that pharma demand is improving, but academic and government funding remains an area of uncertainty.
Catalysts in Upcoming Quarters
Looking ahead, the StockStory team will monitor (1) ongoing adoption and revenue mix from new diagnostic test launches, (2) whether bioprocessing equipment demand moves beyond flat growth, and (3) stabilization in life sciences and academic funding. Execution on cost savings and the pace of recovery in China and academic markets will also be key indicators of Danaher’s ability to deliver on its guidance.
Danaher currently trades at $218.44, down from $235.75 just before the earnings. Is there an opportunity in the stock?Find out in our full research report (it’s free).
Our Favorite Stocks Right Now
If your portfolio success hinges on just 4 stocks, your wealth is built on fragile ground. You have a small window to secure high-quality assets before the market widens and these prices disappear.
Don’t wait for the next volatility shock. Check out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.